- Home
- PLX vs VGZ Comparison
PLX vs VGZ Comparison
Compare PLX & VGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- VGZ
- Stock Information
- Founded
- PLX 1993
- VGZ 1983
- Country
- PLX United States
- VGZ United States
- Employees
- PLX N/A
- VGZ N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- VGZ
- Sector
- PLX Health Care
- VGZ
- Exchange
- PLX Nasdaq
- VGZ Nasdaq
- Market Cap
- PLX 160.2M
- VGZ 131.1M
- IPO Year
- PLX 1998
- VGZ N/A
- Fundamental
- Price
- PLX $1.58
- VGZ $1.25
- Analyst Decision
- PLX Strong Buy
- VGZ Strong Buy
- Analyst Count
- PLX 1
- VGZ 1
- Target Price
- PLX $15.00
- VGZ $2.75
- AVG Volume (30 Days)
- PLX 1.4M
- VGZ 832.2K
- Earning Date
- PLX 05-09-2025
- VGZ 05-01-2025
- Dividend Yield
- PLX N/A
- VGZ N/A
- EPS Growth
- PLX N/A
- VGZ N/A
- EPS
- PLX 0.05
- VGZ 0.08
- Revenue
- PLX $59,764,000.00
- VGZ N/A
- Revenue This Year
- PLX $65.02
- VGZ N/A
- Revenue Next Year
- PLX $57.34
- VGZ N/A
- P/E Ratio
- PLX $32.18
- VGZ $15.08
- Revenue Growth
- PLX 0.18
- VGZ N/A
- 52 Week Low
- PLX $0.82
- VGZ $0.46
- 52 Week High
- PLX $3.10
- VGZ $1.30
- Technical
- Relative Strength Index (RSI)
- PLX 30.32
- VGZ 68.01
- Support Level
- PLX $1.52
- VGZ $1.13
- Resistance Level
- PLX $1.79
- VGZ $1.25
- Average True Range (ATR)
- PLX 0.09
- VGZ 0.08
- MACD
- PLX -0.01
- VGZ 0.01
- Stochastic Oscillator
- PLX 26.44
- VGZ 88.16
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.